An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

ACTIVE_NOT_RECRUITING

Melanoma Institute Australia, North Sydney

ACTIVE_NOT_RECRUITING

Westmead Hospital, Westmead

ACTIVE_NOT_RECRUITING

Princess Alexandra Hospital, Woolloongabba

RECRUITING

St John of God Hospital Subiaco, Subiaco

ACTIVE_NOT_RECRUITING

Affinity Clinical Research, Murdoch

RECRUITING

NYU Langone Medical Center, New York

RECRUITING

Lombardi Cancer Center, Washington D.C.

RECRUITING

Northside Hospital, Atlanta

RECRUITING

Orlando Health UF Health Cancer Center, Orlando

RECRUITING

Sarah Cannon Cancer Center, Nashville

RECRUITING

UPMC Hillman Cancer Center, Chicago

RECRUITING

Washington University School of Medicine, St Louis

RECRUITING

Texas Oncology PA, Dallas

RECRUITING

University of Colorado Cancer Center, Aurora

RECRUITING

University of Arizona, Tucson

RECRUITING

Angeles Clinic and Research Institute, Santa Monica

RECRUITING

California Pacific Medical Center Research Institute -CPMCRI, San Francisco

RECRUITING

Providence Cancer Institute, Portland

RECRUITING

Smilow Cancer Center at Yale New Haven Hospital, New Haven

RECRUITING

Massachusetts General Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

RECRUITING

Hackensack University Medical Center, Hackensack